CLINICAL_TRIALS trial_result · 2026-03-27

Clinical Trial Update: A Study to Investigate the Effect of 0.003% AR-15512 on Subjects With Dry Eye Disease [Phase 3]

A Phase 3 trial evaluating AR-15512 (0.003%) for Dry Eye Disease has completed, with results posted on 2026-03-27.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Alcon Research | Conditions: Dry Eye Disease | Phase 3 | Status: COMPLETED | Results posted: 2026-03-27